Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar;36(3):560-4.
doi: 10.3899/jrheum.080828. Epub 2009 Feb 4.

Prednisone, lupus activity, and permanent organ damage

Affiliations

Prednisone, lupus activity, and permanent organ damage

Mae Thamer et al. J Rheumatol. 2009 Mar.

Abstract

Objective: To estimate the effect of corticosteroids (prednisone dose) on permanent organ damage among persons with systemic lupus erythematosus (SLE).

Methods: We identified 525 patients with incident SLE in the Hopkins Lupus Cohort. At each visit, clinical activity indices, laboratory data, and treatment were recorded. The study population was followed from the month after the first visit until June 29, 2006, or attainment of irreversible organ damage, death, loss to follow-up, or receipt of pulse methylprednisolone therapy. We estimated the effect of cumulative average dose of prednisone on organ damage using a marginal structural model to adjust for time-dependent confounding by indication due to SLE disease activity.

Results: Compared with non-prednisone use, the hazard ratio of organ damage for prednisone was 1.16 (95% CI 0.54, 2.50) for cumulative average doses > 0-180 mg/month, 1.50 (95% CI 0.58, 3.88) for > 180-360 mg/month, 1.64 (95% CI 0.58, 4.69) for > 360-540 mg/month, and 2.51 (95% CI 0.87, 7.27) for > 540 mg/month. In contrast, standard Cox regression models estimated higher hazard ratios at all dose levels.

Conclusion: Our results suggest that low doses of prednisone do not result in a substantially increased risk of irreversible organ damage.

PubMed Disclaimer

Conflict of interest statement

All authors declare there are no conflicts of interest in the development of this manuscript and all related research.

References

    1. Goldblatt F, Isenberg DA. New therapies for systemic lupus erythematosus. Clin Exp Immunology. 2005;140:205–212. - PMC - PubMed
    1. Karlson EW, Daltroy LH, Lew RA, Wright EA, et al. The relationship between of socioeconomic status, race and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:47–56. - PubMed
    1. Zonana-Nacach a, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43:1801–1808. - PubMed
    1. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1955–1959. - PubMed
    1. Toloza SM, Roseman JM, Alarc#x000F3;n GS, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum. 2004;50:3177–3186. - PubMed

Publication types